How are you considering use of inavolisib/palbociclib/fulvestrant over ET doublets for patients with high risk disease features such as visceral metastases, visceral crisis, high tumor burden?  

I would favor deployment of the triplet regimen from the INAVO120 trial in a real-world patient population that mirrors the inclusion criteria for the clinical trial. For example, I would utilize this in routine clinical practice for patients on adjuvant endocrine therapy (typically with an aromatas...

I am considering adding the inavolisib to fulvestrant with CDK4/6i for patients who would have met eligibility criteria for the study. These were high-risk patients with measurable PIK3CA-mutated, hormone receptor-positive, HER2-negative tumors. Their cancer recurred within 12 months of stopping adj...